Biotechnology
10 CFOs in Biotechnology
These ten finance executives currently serve as chief financial officers of biotechnology companies. A reader can learn how biotech CFOs plan cash runway, raise capital, work with investors and build finance teams while research programs move forward.
Professionals to explore
01—10Amy Parison
LinkedInExperience: Chief Financial Officer · Editas Medicine
Chief Financial Officer at Editas Medicine since March 2025; the profile describes Editas as a gene editing company focused on developing CRISPR medicines for people with serious diseases. At Editas, also Senior Vice President, Finance (2025) and VP of Finance and Corporate Controller (2022–2025). Former Senior Director, Corporate Controller at Rubius Therapeutics (2021–2022).
Anne Doering
LinkedInExperience: Chief Financial Officer · Vivoryon Therapeutics N.V.
Chief Financial Officer at Vivoryon Therapeutics N.V. since March 2024; the profile describes Vivoryon as a precision medicine company and a Biotechnology Research company. At Vivoryon, also Chief Strategy & Investor Relations Officer (2023–2024) and Head of Investor Relations (2023). Former Director, Investor Relations at BioNTech SE (2022) and Director, Group Strategy at Merck KGaA (2020–2021).
Ellen Snow
LinkedInExperience: Chief Financial Officer · Mercy BioAnalytics, Inc.
Chief Financial Officer at Mercy BioAnalytics, Inc. since December 2025; the profile describes Mercy BioAnalytics as a Biotechnology Research company working on extracellular vesicles for early-stage cancer. Former Interim CFO, self-employed (2024–2025), and SVP, CFO and Treasurer at Akebia Therapeutics (2023–2024).
Geoffrey Parker
LinkedInExperience: Executive Vice President and Chief Financial Officer · Allogene Therapeutics
Executive Vice President and Chief Financial Officer at Allogene Therapeutics since October 2023; the profile describes Allogene as a Biotechnology company. Former Chief Operating Officer, Chief Financial Officer and Executive Vice President at Tricida, Inc. (2017–2023). Board Member at Perrigo Company plc since 2016, and former Board Member at ChemoCentryx (2009–2022).
Jim Gibson
LinkedInExperience: Chief Financial Officer · PacBio
Chief Financial Officer at PacBio since March 2025; the profile describes PacBio as a Biotechnology Research company that provides long-read sequencing for genomes, transcriptomes and epigenomes. Former Chief Financial Officer at Sequoia (2023–2025), Willow Innovations, Inc. (2021–2022) and BioElectron Technology Corporation (2017–2019), which the profile notes was acquired by PTC Therapeutics in October 2019.
Kathleen Borthwick
LinkedInExperience: Chief Financial Officer · Passage Bio
Chief Financial Officer at Passage Bio since March 2024, after serving there as SVP of Finance, Interim Chief Financial Officer (2021–2024); the profile describes Passage Bio as a genetic medicines company focused on CNS disorders. Former Group Finance Lead, Medical Devices (2020–2021) and Sr. Director Janssen EMEA Mid-Sized Markets (2018–2020) at Johnson & Johnson.
Kathy Bergsteinsson
LinkedInExperience: Chief Financial Officer · Tessera Therapeutics
Chief Financial Officer at Tessera Therapeutics since October 2025; the profile describes Tessera as an early-stage life sciences company pioneering Gene Writing. Former Chief Financial Officer at Affini-T Therapeutics (2023–2025), and Managing Director - Equity Capital Markets (2011–2023) and Vice President - Mergers and Acquisitions Department (2005–2010) at Morgan Stanley.
Michael Mason
LinkedInExperience: Chief Financial Officer · Pioneering Medicines
Chief Financial Officer at Pioneering Medicines since November 2024; the profile describes it as a Biotechnology Research company and names Flagship Pioneering alongside it. Former Chief Financial Officer at Karyopharm Therapeutics Inc. (2019–2024), Vice President of Finance & Treasurer at Alnylam Pharmaceuticals (2005–2019) and Controller at Praecis Pharmaceuticals (2000–2005).
Robert Renninger
LinkedInExperience: Chief Financial Officer · LeonaBio
Chief Financial Officer at LeonaBio since December 2025; the profile describes LeonaBio as a Biotechnology company headquartered in Bothell, Washington. At LeonaBio, also SVP Finance and Accounting (2025), VP Finance and Accounting (2022–2025), Senior Director of Finance (2020–2022) and Director of Finance (2020).
Vishaal Turakhia
LinkedInExperience: Chief Financial Officer · Endeavor BioMedicines
Chief Financial Officer at Endeavor BioMedicines since March 2024; the profile describes Endeavor as a clinical-stage biotechnology company developing medicines. Former Managing Director Healthcare Investment Banking at Piper Sandler (2019–2024), Vice President Healthcare Investment Banking at Bank of America Merrill Lynch (2018–2019) and RBC Capital Markets (2012–2018), and Analyst Biotech Equity Research at Goldman Sachs (2010–2012).
Choose the right perspective
Match the person's background to your question, since a CFO who came from investment banking or equity capital markets and one who rose through corporate finance and controllership tend to see financing and operations differently. Also consider the company stage each person works in, because early private biotechs and public companies face different reporting and fundraising demands.
Questions to take into the conversation
- 01How do you plan cash runway and decide when to raise the next round or go to the public markets?
- 02Which milestones do you tie spending to when several research programs compete for the same budget?
- 03How do you build a finance and accounting team that can handle public-company reporting at a biotech?
Reaching CFOs in Biotechnology
How can I contact one of these CFOs in Biotechnology?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 10 companies, including Editas Medicine; Vivoryon Therapeutics N.V. and Mercy BioAnalytics, Inc., based on profile data retrieved on October 3, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach CFOs in Biotechnology?
You choose the offer, starting at $5 per person. It includes Instant Expert's 20% fee, so an offer that pays the person $100 costs you $125. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.
Request a correction or removal